PCM
GEVA

Palisade Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Palisade Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-120,779
Closed -$12.7M – 522
2014
Q2 		$12.7M Sell
120,779
-15,932
-12% -$1.36M 0.31% 122
2014
Q1 		$11.3M Buy
+136,711
New +$12.6M 0.28% 141

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Palisade Capital Management's GEVA Position: Q3 2014 in Review

Palisade Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2014, closing a stake of 120,779 shares — an estimated $12.7M sold.

Palisade Capital Management first reported a position in GEVA in Q1 2014 and held it in 2 quarters. The position peaked at $12.7M in Q2 2014. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

  • Palisade Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • Palisade Capital Management sold 120,779 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $12.7M.
  • Palisade Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 2 quarters.
  • Palisade Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $12.7M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on Palisade Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.